Immuron IMRN 深 滬
已收盤 11-06 16:00:00 美东时间
0.8312
-0.019
-2.20%
華盛通- 最 高0.895
- 今 開0.84
- 成交量 1.16万股
- 最 低 0.78
- 昨 收 0.8499
- 總市值 670.88万
- 52周最高 1.99
- 市盈率 靜 --
- 換手率 0.14%
- 52周最低 0.6765
- 委 比 -99.00%
- 總股本 807.12万
- 歷史最高 28.99
- 量 比 0.47
- 振 幅 13.53%
- 歷史最低 0.6765
- 每 手 1
- 風險率 0.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immuron trims ATM facility to US$2 million while preserving funding flexibility
Immuron Limited ( ($AU:IMC) ) just unveiled an update. Immuron Limited has upda...
10-27 10:17
Immuron continued quarterly sales growth
Immuron Limited reported Q1 FY27 sales growth of 9% globally, with strong performance in Australia (+14%), Canada (+286%), and weaker results in the U.S. (-19%). Australia's growth was driven by Travelan® brand relaunch and increased market penetration. The U.S. decline was attributed to inventory challenges, but future sales are expected to improve. Canada's surge was due to brand awareness efforts. Travelan® continues to gain market share in ph...
10-27 10:00
Immuron lifts Q1 sales on Travelan surge despite U.S. softness
An announcement from Immuron Limited ( ($AU:IMC) ) is now available. Immuron re...
10-27 06:37
Travelan® Phase 2 Study Results Published
Immuron Limited announced the publication of Phase 2 clinical trial data for Travelan® in *Scientific Reports*. The study showed a statistically significant 50% reduction in ETEC-related adverse events compared to placebo, despite not meeting the primary efficacy endpoints due to a lower-than-expected placebo attack rate. Key findings included reductions in diarrhea severity and early antibiotic use, supporting Travelan's potential protective ben...
10-13 10:00
Immuron advances Travelan after Phase 2 data published in Nature journal
Immuron Limited ( ($AU:IMC) ) has issued an update. Immuron has reported that d...
10-13 06:39
Immuron Showcases Oral Antibody Platform at Coffee Microcaps Conference
Immuron Limited ( ($AU:IMC) ) just unveiled an announcement. Immuron’s chief ex...
09-22 07:37
Immuron Stock Surges Friday: What's Driving the Action?
Shares of Immuron Limited (NASDAQ:IMRN) are surging Friday morning following news that the Australian biopharmaceutical company signed an exclusive agreement to launch PROIBS gut health product in the United States. Here’s what investors need to know. Immuron stock is surging to new heights today. W...
09-04 21:11
Market-Moving News for September 4th
PL: 13% | PL stock has given up its prior gain. Planet Labs shares were trading higher after the company reported better-than-expected Q2 sales results. IMRN: 58% | Immuron Announces Exclusive U.S. Distribution Agreement For Calmino Group's Digestive Health Product PROIBS PATH: -10% | PATH stock...
09-04 19:22
Immuron shares are trading higher after the company announced an exclusive US distribution agreement for PROIBS with Calmino group.
Immuron shares are trading higher after the company announced an exclusive US distribution agreement for PROIBS with Calmino group.
09-04 19:20
Immuron to launch PROIBS® in the United States
Immunon Limited has signed an exclusive distribution agreement with Calmino group AB to launch PROIBS® in the U.S. market. PROIBS®, a medical device for digestive health, addresses abdominal pain, bloating, and bowel issues. With a market value of $4.16 billion in the U.S., PROIBS® targets a subset of this market. Derived from Aloe barbadensis Mill., PROIBS® supports intestinal health and has shown positive results in 94% of users. Immunon aims t...
09-04 10:00
